Related references
Note: Only part of the references are listed.Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs
Jin Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Naomi B. Haas et al.
LANCET (2016)
Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Andrew J. Armstrong et al.
LANCET ONCOLOGY (2016)
Emerging therapies: angiogenesis inhibitors for ovarian cancer
Amanda L. Jackson et al.
EXPERT OPINION ON EMERGING DRUGS (2015)
Serum microRNA-205 as a novel biomarker for cervical cancer patients
Quanhui Ma et al.
CANCER CELL INTERNATIONAL (2014)
Arf tumor suppressor and miR-205 regulate cell adhesion and formation of extraembryonic endoderm from pluripotent stem cells
Chunliang Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Losartan Slows Pancreatic Tumor Progression and Extends Survival of SPARC-Null Mice by Abrogating Aberrant TGFβ Activation
Shanna A. Arnold et al.
PLOS ONE (2012)
miR-205 Expression Promotes Cell Proliferation and Migration of Human Cervical Cancer Cells
Hong Xie et al.
PLOS ONE (2012)
miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines
Huijuan Chai et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2011)
Role of the Renin-Angiotensin System in Gynecologic Cancers
K. Ino et al.
CURRENT CANCER DRUG TARGETS (2011)
Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer
Chang Gong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population
Jing Dong et al.
CARCINOGENESIS (2010)
VEGF Hypersecretion as a Plausible Mechanism for Pseudo-Meigs' Syndrome in Advanced Colorectal Cancer
Yoshihisa Okuchi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
microRNA-205 Regulates HER3 in Human Breast Cancer
Marilena V. Iorio et al.
CANCER RESEARCH (2009)
miR-205 Exerts Tumor-Suppressive Functions in Human Prostate through Down-regulation of Protein Kinase Cε
Paolo Gandellini et al.
CANCER RESEARCH (2009)
Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells
Nalinie S. Wickramasinghe et al.
NUCLEIC ACIDS RESEARCH (2009)
MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells
Thales Papagiannakopoulos et al.
CANCER RESEARCH (2008)
Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome
Yuan Xue et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Tumour invasion and metastasis initiated by microRNA 10b in breast cancer
Li Ma et al.
NATURE (2007)
MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1)
Shuomin Zhu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
VEGF-C and COX-2 expression in papillary thyroid cancer
Paivi Siironen et al.
ENDOCRINE-RELATED CANCER (2006)
Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination
T Suganuma et al.
CLINICAL CANCER RESEARCH (2005)
Activation of invasiveness of cervical carcinoma cells by angiotensin II
F Kikkawa et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2004)
An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells
N Kurikawa et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
Share Paper
